KLK3, kallikrein related peptidase 3, 354

N. diseases: 358; N. variants: 19
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 AlteredExpression disease BEFREE The AUC-ROCs distinguishing nonprostate cancer vs prostate cancer, nonprostate cancer plus low Gleason Grade Group and low volume vs remaining prostate cancer with a higher Gleason Grade group or a higher volume on the PHI (Prostate Health Index) were significantly superior to the AUC-ROCs of prostate specific antigen and free-to-total prostate specific antigen. 31430244 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE This translational study supported preclinical data demonstrating the pro-tumorigenic capacity of cellular CD105 and provide a blood-based biomarker, sCD105, for prostate cancer recurrence in prostatectomy patients with PSA levels ≤ 10 ng/ml. 31648185 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE A 75-year-old man, treated with curative intent for histopathologically proven prostate cancer (initial prostate-specific antigen, 27 ng/mL; Gleason 4 + 5 = 9) through external beam radiation therapy in 2010 in combination with 3 years of androgen deprivation therapy (leuprorelin), underwent F-DCFPyL PET/CT for biochemical recurrence with a prostate-specific antigen of 4.1 ng/mL in February 2019. 31361646 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 AlteredExpression disease BEFREE Prostate specific antigen levels and proportion of biopsy positive cores are independent predictors of upgrading patterns in low risk prostate cancer. 30298710 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE Among patients with serum PSA level of 4 to 10 ng/mL (n = 121), the AMACR score was significantly higher in patients with PCa (<i>P</i> = 0.0002), while serum PSA showed no difference (<i>P</i> = 0.3023). 31793344 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE Seven hundred three (n = 703) prostate cancer (PCa) patients with confirmed PSA failure after radical therapy were enrolled. 31492993 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation disease BEFREE Prostate cancer (PCa) risk calculators (RCs) with prostate-specific antigen (PSA) and other risk factors can greatly improve the accurate prediction of potential risk of PCa compared to PSA. 31187780 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE Individualized risk-adapted algorithms in prostate cancer (PCa) diagnosis using predictive prebiopsy variables in addition to prostate-specific antigen value may result in a considerable reduction of unnecessary systematic biopsies. 30868240 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE The resulting area under the receiver operating characteristic curve (AUC) to predict csPCa was 0.76 for PI-RADS v2, 0.59 for age, and 0.67 for PSA density. 31690449 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4-10 ng ml<sup>-1</sup>). 31169140 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE Prostate specific antigen (PSA) monitoring and histopathological examination of tumor biopsies remain gold standards in PCa diagnostics. 31577907 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE Over the past decade prostate cancer (PCa) diagnostic approaches have evolved away from aggressive prostate-specific antigen (PSA) screening. 31235801 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE A 72-year-old man with a history of T1cN0M0 prostate adenocarcinoma and rising prostate-specific antigen underwent a fluciclovine PET/CT scan that showed high uptake in several para-aortic nodes, suspicious for prostate cancer. 31652158 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE Rates of clinically significant prostate cancer in African Americans increased significantly following the 2012 US Preventative Services Task Force recommendation against prostate specific antigen screening: A Single Institution Retrospective Study. 31750596 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE The differences in f/t PSA, PV, and PSAD for patients with and without PCa were statistically significant.(p < .001). 30862227 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation disease BEFREE We identified 6.509 patients with prostate cancer who had received hormonal therapy with a post-hormonal therapy PSA ≥2ng/mL, 363 of whom had non-metastatic, castrate-resistant prostate cancer. 31851457 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE The objective of this study was to assess the positive predictive value of prostate specific antigen and prostate specific antigen density for prostate cancer risk following holmium laser enucleation of the prostate. 31487219 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone. 31665354 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE Prostate-specific antigen (PSA) is the marker for prostate cancer puncture screening. 30913093 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE The median follow-up was 66.6 mo.Patients with CDK12 mutant prostate cancer exhibited shorter time to metastasis (median = 34.9 mo, p =  0.004) and development of castration-resistant disease (median = 32.7 mo, p <  0.001), compared with other genomic subtypes, with shorter time to PSA progression on first-line ARPI treatment of metastatic castration-resistant disease (median = 3.6 mo, p =  0.0219). 31640893 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE This clinical case study adds evidences to the fact that cardiogenic shock is an important cause of PSA FP results, therefore it cannot be used as a reliable marker of PCa in this clinical condition and positive results should be properly interpreted. 31765638 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE <b>Purpose:</b> Prostate-specific antigen (PSA) is a sensitive but unspecific marker for prostate cancer (PC) detection, which may result in harms including overdiagnosis and overtreatment. 31692391 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 AlteredExpression disease BEFREE Moreover, among 143 patients with PCa who received radical prostatectomy (RP), the AUCs of LDN-PSA, LDN-PSAD, and PSAD levels (0.750, 0.812, and 0.769, respectively) detected in patients with a pathologic Gleason grade group ≥ 2 were significantly higher (P = .0170, P = .0028, and P = .0003, respectively) than that of PSA (0.578). 31711843 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE The use of artificial urinary sphincter (AUS) for the treatment of stress urinary incontinence has become more prevalent, especially in the "prostate-specific antigen (PSA)-era", when more patients are treated for localized prostate cancer. 31736473 2020
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE We sought to determine the extent to which US Preventive Services Task Force (USPSTF) 2012 Grade D recommendations against prostate-specific antigen screening may have impacted recent prostate cancer disease incidence patterns in the United States across stage, National Comprehensive Cancer Network (NCCN) risk groups, and age groups. 31794057 2020